Gene · 10038
Papers2,674
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,674
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| In Vitro Anticancer Activity and In Silico Target Profiling of 5-(Piperazin-1-ylsulfonyl)-1,3-oxazole-4-carbonitriles. | Int J Mol Sci | 2026 | 41752072 | PubTator, text mining | PubMed |
| Special Issue "Cancer Biology: From Genetic Aspects to Treatment: 1st Edition". | Int J Mol Sci | 2026 | 41752022 | PubTator, text mining | PubMed |
| Synergistic Antitumor Activity of Curcumin and the PARP1 Inhibitor PJ34 in Platinum-Sensitive and Resistant Ovarian Cancer Cells. | Cancers (Basel) | 2026 | 41749873 | PubTator, text mining | PubMed |
| Synergistic Cellular Toxicity from Inhibition of Poly(ADP-ribose) Glycohydrolase (PARG) and Ubiquitin-Specific Protease 1 (USP1). | Toxics | 2026 | 41745836 | PubTator, text mining | PubMed |
| Decoding Leukemic Stem Cells in AML: From Identification to Targeted Eradication. | Diseases | 2026 | 41745087 | PubTator, text mining | PubMed |
| Tankyrases and Their Binding Proteins: Origins of Their Roles in Diverse Cellular Pathways. | Cells | 2026 | 41744791 | PubTator, text mining | PubMed |
| Cellular strategies for repairing trapped protein-DNA complexes. | Front Pharmacol | 2026 | 41743125 | PubTator, text mining | PubMed |
| Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation. | PeerJ | 2026 | 41736752 | PubTator, text mining | PubMed |
| Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis. | Ann Med | 2026 | 41725538 | PubTator, text mining | PubMed |
| Regulation of Activity of DNA Polymerases β and λ by XRCC1, PARP1, and PARP2 Proteins. | Biochemistry (Mosc) | 2026 | 41702736 | PubTator, text mining | PubMed |
| Palladium-catalysed synthesis of small-molecule epigenetic inhibitors as anticancer therapeutics. | J Enzyme Inhib Med Chem | 2026 | 41693699 | PubTator, text mining | PubMed |
| Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based PARP1/ATR dual inhibitors. | J Enzyme Inhib Med Chem | 2026 | 41693691 | PubTator, text mining | PubMed |
| The Contribution of Genetic Modifiers to Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers. | Cancers (Basel) | 2026 | 41681824 | PubTator, text mining | PubMed |
| Design, synthesis and biological evaluation of novel pyrrolo[1,2-b]pyridazin-2(1H)-ones as selective PARP1 inhibitors for cancer therapy. | Eur J Med Chem | 2026 | 41672027 | PubTator, text mining | PubMed |
| Discovery of novel olaparib-β-carboline hybrids for treating BRCA-deficient triple negative breast cancer. | Bioorg Med Chem | 2026 | 41643574 | PubTator, text mining | PubMed |
| Letter to the Editor (Correspondence): Re: Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer. | Lab Invest | 2026 | 41643284 | PubTator, text mining | PubMed |
| Synthetic strategies and therapeutic insights into FDA-approved indole-containing drugs. | J Enzyme Inhib Med Chem | 2026 | 41601150 | PubTator, text mining | PubMed |
| Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. | Proc Natl Acad Sci U S A | 2026 | 41591905 | PubTator, text mining | PubMed |
| Automodification of N-terminal serine residues facilitates PARP2 release from DNA. | FEBS J | 2026 | 41578964 | PubTator, text mining | PubMed |
| Transcriptomic characterization of the aberrant alternative splicing in skeletal muscles of sarcopenia patients. | Sci Rep | 2026 | 41545573 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10038/papers?page=3